Clinical Trial – A Study of Niclosamide in Patients With Resectable Colon Cancer – Colon Cancer

This study evaluates the safety of Niclosamide in patients with colon cancer that are undergoing primary resection of their tumor. This is a phase I study with three dosage levels to determine the maximum tolerated dose (MTD).

Study Type  : Interventional  (Clinical Trial)
Estimated Enrollment  : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Phase I Study of Niclosamide in Patients With Resectable Colon Cancer
Actual Study Start Date  : April 17, 2017
Estimated Primary Completion Date  : July 2020
Estimated Study Completion Date  : July 2022
Contacts
Contact: Michael A Morse, MD 919-684-5705 michael.morse@dm.duke.edu
Contact: Wanda Honeycutt, RN BSN CCRP 919-668-1861 wanda.honeycutt@dm.duke.edu
Locations
United States, North Carolina
Duke University Recruiting
Durham, North Carolina, United States, 27710
Contact: Michael Morse, MD    919-684-5705    michael.morse@duke.edu
ClinicalTrials.gov Identifier: NCT02687009

 

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.